[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100334406":3},{"organization":4,"armGroups":7,"interventions":27,"overallOfficials":34,"centralContacts":39,"locations":45,"responsibleParty":91,"collaborators":93,"id":95,"slug":96,"hasResults":97,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":97,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":33,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":118,"overallStatus":77,"whyStopped":33,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":128},{"fullName":5,"class":6},"University of Oklahoma","OTHER",[8,14,19,23],{"label":9,"type":10,"description":11,"interventionNames":12},"Standard therapy - Acute leukemia cohort","ACTIVE_COMPARATOR","The Arm will accrue patients receiving standard therapy from the high-risk acute leukemia cohort (18 patients).",[13],"Drug: FLT",{"label":15,"type":16,"description":17,"interventionNames":18},"Immunotherapy - Acute leukemia cohort","EXPERIMENTAL","The Arm will accrue patients receiving immunotherapy from the high-risk acute leukemia cohort (18 patients).",[13],{"label":20,"type":10,"description":21,"interventionNames":22},"Standard therapy - Myeloma cohort","The Arm will accrue patients receiving standard therapy from the myeloma cohort (9 patients).",[13],{"label":24,"type":16,"description":25,"interventionNames":26},"Immunotherapy - Myeloma cohort","The Arm will accrue patients receiving immunotherapy from the myeloma cohort (9 patients).",[13],[28],{"type":29,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"DRUG","FLT","F18 labeled thymidine PET\u002FCT scans will be performed before and after patient receives therapies.",[15,24,9,20],null,[35],{"name":36,"affiliation":37,"role":38},"Jennifer Holter, MD","Stephenson Cancer Center","PRINCIPAL_INVESTIGATOR",[40],{"name":41,"role":42,"phone":43,"phoneExt":33,"email":44},"Heme Onc Lead Nurse","CONTACT","1-405-271-8777","SCC-IIT-Office@ouhsc.edu",[46,60,75],{"facility":47,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":33},"Children's National Health System","WITHDRAWN","Washington D.C.","District of Columbia","20010","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-77.03637,38.89511,{"lat":58,"lon":57},{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":52,"countryCode":53,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Emory University","NOT_YET_RECRUITING","Atlanta","Georgia","30322",{"type":55,"coordinates":67},[68,69],-84.38798,33.749,{"lat":69,"lon":68},[72,74],{"name":73,"role":42,"phone":33,"phoneExt":33,"email":33},"Kirsten M Williams, MD",{"name":73,"role":38,"phone":33,"phoneExt":33,"email":33},{"facility":76,"status":77,"city":78,"state":79,"zip":80,"country":52,"countryCode":53,"cosmosGeoPoint":81,"geoPoint":85,"contacts":86},"University of Oklahoma Health Sciences Center","RECRUITING","Oklahoma City","Oklahoma","73117",{"type":55,"coordinates":82},[83,84],-97.51643,35.46756,{"lat":84,"lon":83},[87],{"name":88,"role":42,"phone":89,"phoneExt":33,"email":90},"Jennifer Holter Chakrabarty, MD","405-271-4022","jholter2@ouhsc.edu",{"type":92,"investigatorFullName":33,"investigatorTitle":33,"investigatorAffiliation":33,"oldNameTitle":33,"oldOrganization":33},"SPONSOR",[94],{"name":61,"class":6},"100334406","phase-1-pilot-imaging-study-of-leukemia-100334406",false,"NCT03633955","Pilot Imaging Study of Leukemia","Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging","REALIZE","Inclusion Criteria:\n\n1. Aged 4 to 80 years\n2. Evidence of high-risk hematopoietic malignancy with relapsed\u002Frefractory disease: acute lymphocytic leukemia, Acute myeloid leukemia, Ambiguous lineage leukemia, myeloma\n3. Karnofsky\u002FLansky score of ≥ 50\n4. Agree to use contraceptive measures during study protocol participation (when age appropriate)\n5. Patient or parent\u002Fguardian capable of providing informed consent.\n6. Ability to undergo 18F FLT imaging without sedation\n7. Bilirubin \\\u003C 2.5 mg\u002FdL, AST\u002FALT \\\u003C5x upper limit of normal, Serum creatinine \\\u003C 1.0 or 2x the upper limit of normal (whichever is higher)\n8. Pulse oximetry of \\> 90% on room air\n9. Ability to undergo 18F FLT imaging without sedation\n10. Anticipated immunotherapy (Arm A to include patients who received immune therapy with co-enrollment on a separate protocol or other immunotherapy) and Arm B, those who received other non-immune therapies to treat their cancers (excludes HSCT but includes chemotherapy or non-HSCT radiotherapy).\n\nExclusion Criteria:\n\n1. Patients with uncontrolled infections\n2. Pregnancy or lactating\n3. History of prior fluorothymidine allergy or intolerance.","ALL","4 Years","80 Years",{"count":107,"type":108},60,"ESTIMATED","INTERVENTIONAL",[111],"PHASE1","This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.",[114,115,116,117],"Acute Lymphocytic Leukemia","Acute Myeloid Leukemia","Ambiguous Lineage Leukemia or Lymphoma","Myeloma",[30],"2026-04-21",{"date":121,"type":122},"2026-04-23","ACTUAL",{"date":124,"type":122},"2023-01-19",{"date":126,"type":108},"2029-04",{"name":5,"class":6},3]